

SUBCUTANEOUS PORT FOR ADMINISTRATION OF HEPARINS

DESCRIPTION OF THE TECHNOLOGY

Long-term administration of low-molecular-weight heparins (LMWHs) is commonly used in patients with or at risk of thromboembolic disease, including cancer patients, pregnant women and certain paediatric patients. These treatments require one or two daily subcutaneous injections over extended periods, which may cause pain, bruising and other local complications, as well as affecting patient comfort and treatment adherence. Although subcutaneous access devices are available for the administration of other drugs, there are currently no solutions specifically designed for repeated LMWH administration, limiting their use in this setting.

An INCLIVA researcher has developed a subcutaneous port specifically designed for the long-term administration of low-molecular-weight heparins. The device provides safe subcutaneous access for repeated administration, with the potential to improve the patient experience, standardise clinical practice and facilitate treatment administration in both hospital and home settings.

APPLICATION

Health / Medical Devices

Health / Haematology, Oncology, Gynaecology, Internal Medicine

COLABORATION SOUGHT

Medical device and healthcare technology companies interested in licensing or co-development agreements for the manufacture and commercialisation of the device.

Hospitals and healthcare organisations interested in the clinical validation and evaluation of the device in both healthcare and home settings.

ADVANTAGES

- ✓ Specifically designed for LMWH administration.
- ✓ Reduces repeated injections.
- ✓ Improves patient comfort.
- ✓ Standardises clinical practice.
- ✓ Easy to implement in clinical practice..

STATE OF DEVELOPMENT

The device is currently at the conceptual design stage, with a 3D prototype under development. Validation will require prototype manufacturing and preclinical studies prior to clinical evaluation.

INTELLECTUAL PROPERTY RIGHTS

Utility model pending. Application No. U202631177.



CONTACT

INCLIVA Innovation Unit

+34 961 628 922 / 961 628 923

innovacion@incliva.es